Get started
Author

Dianne Carey

Observed names: Carey, Dianne Lauraine, Carey,Dianne, D Carey, D Carey (13283520), D. Carey, Dianne L Carey, Dianne L. Carey
ORCID: 0000-0003-0156-8143
Observed ORCID: 0000-0003-0156-8143
OpenAlex ID: A5058205661
A prospective multicentre study of pharmacist initiated changes to drug therapy and patient management in acute care government funded hospitals
2004 · Michael J. Dooley, Karen M. Allen, et al. · British Journal of Clinical Pharmacology · 246
PDF
No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial
2004 · Andrew Carr, Cassy Workman, et al. · The Lancet · 240
Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection
2007 · Handan Wand, Alexandra Calmy, et al. · AIDS · 196
Anti-influenza hyperimmune intravenous immunoglobulin for adults with influenza A or B infection (FLU-IVIG): a double-blind, randomised, placebo-controlled trial
2019 · Richard T Davey, Eduardo Fernández-Cruz, et al. · The Lancet Respiratory Medicine · 128
PDF
Efficacy and safety of efavirenz 400 mg daily versus 600 mg daily: 96-week data from the randomised, double-blind, placebo-controlled, non-inferiority ENCORE1 study
2015 · Dianne Carey, Rebekah Puls, et al. · The Lancet Infectious Diseases · 113
Pharmacokinetic and Pharmacodynamic Comparison of Once‐Daily Efavirenz (400 mg vs. 600 mg) in Treatment‐Naïve HIV‐Infected Patients: Results of the ENCORE1 Study
2015 · L Dickinson, J Amin, et al. · Clinical Pharmacology & Therapeutics · 75
PDF
Comprehensive Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Evaluation of Once-Daily Efavirenz 400 and 600 mg in Treatment-Naïve HIV-Infected Patients at 96 Weeks: Results of the ENCORE1 Study
2015 · Laura Dickinson, Janaki Amin, et al. · Clinical Pharmacokinetics · 52
PDF
Sulphadiazine desensitization in patients with AIDS and cerebral toxoplasmosis
1991 · Melinda Tenant-Flowers, Michael J. Boyle, et al. · AIDS · 52
Lipid profiles in HIV-infected adults receiving atazanavir and atazanavir/ritonavir: systematic review and meta-analysis of randomized controlled trials
2010 · D. Carey, J. Amin, et al. · Journal of Antimicrobial Chemotherapy · 49
A Randomized, Multicenter, Open-Label Study of Poly-L-Lactic Acid for HIV-1 Facial Lipoatrophy
2007 · Dianne L Carey, David Baker, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 44
Cerebrospinal Fluid Exposure of Efavirenz and Its Major Metabolites When Dosed at 400 mg and 600 mg Once Daily: A Randomized Controlled Trial
2014 · Alan Winston, Alan Winston, et al. · Clinical Infectious Diseases · 31
Simultaneous determination of indinavir, ritonavir and lopinavir (ABT 378) in human plasma by high-performance liquid chromatography
2002 · John Ray, Edna Pang, et al. · Journal of Chromatography B · 29
Evaluation of ultrasound for assessing facial lipoatrophy in a randomized, placebo-controlled trial
2005 · Dianne Carey, Handan Wand, et al. · AIDS · 28
Influence of Rosiglitazone on Flow-Mediated Dilation and Other Markers of Cardiovascular Risk in HIV-Infected Patients with Lipoatrophy
2005 · Jason C Kovacic, Allison Martin, et al. · Antiviral Therapy · 25
Health-Related Quality of Life Outcomes in HIV-Infected Patients Starting Different Combination Regimens in a Randomized Multinational Trial: The INITIO-QoL Substudy
2007 · Raffaella Bucciardini, Vincenzo Fragola, et al. · AIDS Research and Human Retroviruses · 20
An attempt to influence hypnotic and sedative drug use
1992 · Dianne L Carey, Richard O Day, et al. · The Medical Journal of Australia · 19
A Randomized Study of Pharmacokinetics, Efficacy, and Safety of 2 Raltegravir Plus Atazanavir Strategies in ART-Treated Adults
2012 · Dianne Carey, Sarah L. Pett, et al. · JAIDS Journal of Acquired Immune Deficiency Syndromes · 18
Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015
2017 · Dominic E Dwyer, Ruth Lynfield, et al. · Open Forum Infectious Diseases · 17
PDF
Efavirenz plasma concentrations did not predict cessation of therapy due to neuropsychiatric symptoms in a large randomized trial
2009 · Tim RH Read, Dianne Carey, et al. · AIDS · 17
Efavirenz 400 mg daily remains non‐inferior to 600 mg: 96 week data from the double‐blind, placebo‐controlled ENCORE1 study
2014 · Dianne Carey · Journal of the International AIDS Society · 15
PDF
Restorative interventions for HIV facial lipoatrophy.
2008 · Dianne Carey, Steven Liew, et al. · PubMed · 14
Poly‐ l ‐lactic acid for HIV‐1 facial lipoatrophy: 48‐week follow‐up
2009 · D Carey, D Baker, et al. · HIV Medicine · 13
PDF
Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy*
2008 · A Calmy, D Carey, et al. · HIV Medicine · 12
PDF
Drug interactions with fluconazole
1992 · Susan Tett, Dianne Carey, et al. · The Medical Journal of Australia · 11
Using Clinical Research Networks to Assess Severity of an Emerging Influenza Pandemic
2018 · Lone Simonsen, Elizabeth Higgs, et al. · Clinical Infectious Diseases · 8
Works count: 122
Citation count: 1,490
H-index: 17
I10-index: 24
Year
Topic
Type